Actively Recruiting
A Study to Test How Well Different Doses of BI 3031185 Are Tolerated by Healthy Men
Led by Boehringer Ingelheim · Updated on 2026-02-17
60
Participants Needed
1
Research Sites
82 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3031185 in healthy male subjects following administration of multiple rising doses.
CONDITIONS
Official Title
A Study to Test How Well Different Doses of BI 3031185 Are Tolerated by Healthy Men
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy male subjects as confirmed by medical history, physical exam, vital signs, ECG, and lab tests
- Age 18 to 50 years (inclusive)
- Body Mass Index (BMI) from 20.0 to 29.9 kg/m2 and body weight at least 60 kg
- Signed informed consent according to ICH-GCP and local laws before joining the trial
You will not qualify if you...
- Any abnormal medical exam findings considered clinically relevant by the investigator
- Systolic blood pressure outside 90 to 139 mmHg, diastolic blood pressure outside 50 to 89 mmHg, or pulse rate outside 50 to 90 bpm at screening
- Laboratory values outside reference ranges deemed clinically relevant by the investigator
- Evidence of any clinically relevant concomitant disease
- Additional exclusion criteria as applicable
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Charité Research Organisation GmbH
Berlin, Germany, 10117
Actively Recruiting
Research Team
B
Boehringer Ingelheim
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here